摘要
Abstract
Objective:To investigate the effect of Ulinastatin on immune function,inflammatory factor and liver function in patients with cirrhosis and liver cancer after operation.Method:Ninety-eight patients with cirrhosis and liver cancer after operation who admitted to Qingdao Shibei District People's Hospital from June 2021 to June 2023 were selected as the subjects of this study,and they were divided into the observation group(n=51)and the control group(n=47)according to the different treatment methods.The control group was given conventional treatment,and the observation group was given Ulinastatin on the basis of the control group.The immune function,inflammatory factors,liver function and complication were compared between two groups.Result:The CD4+,CD4+/CD8+,immunoglobulin G(IgG)and immunoglobulin A(IgA)in the observation group after treatment were higher than those in the control group,while the interleukin-6(IL-6),tumor necrosis factor-α(TNF-α),high-sensitivity C-reactive protein(hs-CRP),soluble interleukin-2 receptor(SIL-2R),alanine aminotransferase(ALT),aspartate aminotransferase(AST),total bilirubin and total bile acid levels were lower than those in the control group,and the differences were statistically significant(P<0.05);the incidence of complications in the observation group(5.88%)was lower than that in the control group(27.66%),and the difference was statistically significant(P<0.05).Conclusion:Ulinastatin adjuvant therapy in patients with cirrhosis and liver cancer can effectively inhibit the level of inflammatory factors,improve immune function and liver function,reduce the incidence of complications,and has high drug safety.关键词
乌司他丁/肝硬化/肝癌/免疫功能/炎症因子/肝功能Key words
Ulinastatin/Cirrhosis/Liver cancer/Immune function/Inflammatory factor/Liver function
